LakeShore Biopharma Co., Ltd.
LSBCF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LSBCF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LSBCF
LakeShore Biopharma Co., Ltd. is a China-based biopharmaceutical company focused on developing PIKA-adjuvanted prophylactic and therapeutic biologics for infectious diseases and cancer, with one marketed product (YSJA™ rabies vaccine) and a pipeline of preclinical and clinical candidates.
Key risk: Capital and liquidity risk
Market Cap
$2.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2025.
LakeShore Biopharma Co., Ltd. is a China-based biopharmaceutical company focused on developing PIKA-adjuvanted prophylactic and therapeutic biologics for infectious diseases and cancer, with one marketed product (YSJA™ rabies vaccine) and a pipeline of preclinical and clinical candidates.
- Has one marketed product, YSJA™ rabies vaccine, generating revenue since October 2020 [sec · filed 2025-07-31].
- Cash & equivalents of $15.0M as of 2025-03-31 [sec]; shareholders' equity of -$699.0M as of 2025-03-31 [sec]; total debt of $57.7M as of 2025-03-31 [sec].
- Net loss of RMB100.0 million ($13.9M) for fiscal year ended March 31, 2025 [sec · filed 2025-07-31].
- Pipeline is based on proprietary PIKA adjuvant technology platform, targeting infectious diseases and cancer [sec · filed 2025-07-31].
- Sales and marketing activities managed across 307 cities in China [sec · filed 2025-07-31].
What works
- Has an approved and revenue-generating product (YSJA™ rabies vaccine) providing commercial experience and infrastructure [sec · filed 2025-07-31].
- Proprietary PIKA immunomodulating technology platform supports a differentiated pipeline of prophylactic and therapeutic biologics [sec · filed 2025-07-31].
- Scalable commercialization infrastructure and accumulated experience across 307 Chinese cities could benefit future product launches [sec · filed 2025-07-31].
What to weigh
- Significant accumulated losses and negative shareholders' equity of -$699.0M as of 2025-03-31 [sec].
- Substantial additional funding likely needed for development and commercialization; may not be available on acceptable terms [sec · filed 2025-07-31].
- All product candidates except YSJA™ are in preclinical or clinical stages and may never receive regulatory approval [sec · filed 2025-07-31].
- Net cash used in operations has been substantial since inception, with net loss of RMB100.0M in fiscal 2025 [sec · filed 2025-07-31].
From the filings
Quoted directly from source documents.
Company has one marketed product generating revenue since October 2020.
“As of the date of this Annual Report, we have one marketed product, YSJA™ rabies vaccine, and we have begun to recognize revenue from sales of YSJA™ rabies vaccine since October 2020.”
SEC filings · July 31, 2025
Net loss for fiscal year ended March 31, 2025 was RMB100.0 million.
“We had net loss of RMB145.5 million, RMB433.5 million and RMB100.0 million ($13.9 million) for the fiscal years ended March 31, 2023, 2024 and 2025, respectively.”
SEC filings · July 31, 2025
Company's pipeline is based on PIKA adjuvant technology.
“Our PIKA adjuvant is based on a novel mechanism of action for adjuvants supported by our PIKA immunomodulating technology platform, through which we are developing prophylactic and therapeutic biologics.”
SEC filings · July 31, 2025
Sales and marketing activities cover 307 cities in China.
“team managed our sales and marketing activities across 307 cities in China.”
SEC filings · July 31, 2025
Risks & what to watch (4)›
Key risks
- Capital and liquidity risk — Substantial additional funding likely needed; may not be available on acceptable terms. Cash $15.0M as of 2025-03-31 [sec].
- Clinical and regulatory risk — All product candidates except YSJA™ are preclinical/clinical and may never receive approval [sec · filed 2025-07-31].
- Commercial dependence on YSJA™ — Revenue depends on YSJA™ rabies vaccine sales; failure to expand sales could materially affect business [sec · filed 2025-07-31].
- Manufacturing and supply risk — Relies on current manufacturing facilities; disruption or failure to meet GMP could harm operations [sec · filed 2025-07-31].
What to watch
- Progress of clinical trials for pipeline candidates, especially any PIKA-adjuvanted programs [sec · filed 2025-07-31].
- Sales growth trajectory of YSJA™ rabies vaccine and expansion into additional Chinese cities [sec · filed 2025-07-31].
- Ability to secure additional financing or partnerships to fund ongoing R&D and commercialization [sec · filed 2025-07-31].
- Regulatory developments for product candidates in China and other jurisdictions [sec · filed 2025-07-31].
Sources: SEC filings · Generated August 13, 2026 · How we verify sources →
Run LakeShore Biopharma Co., Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LakeShore Biopharma Co., Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Frequently asked questions
What is the AI investment thesis for LakeShore Biopharma Co., Ltd.?
LakeShore Biopharma Co., Ltd. is a China-based biopharmaceutical company focused on developing PIKA-adjuvanted prophylactic and therapeutic biologics for infectious diseases and cancer, with one marketed product (YSJA™ rabies vaccine) and a pipeline of preclinical and clinical candidates.
Who is the CEO of LakeShore Biopharma Co., Ltd.?
Mr. Wang Xu is the chief executive officer of LakeShore Biopharma Co., Ltd. (LSBCF).
Where is LakeShore Biopharma Co., Ltd. headquartered?
LakeShore Biopharma Co., Ltd. (LSBCF) is headquartered in Beijing, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.